082270 — GemVax & KAEL Co Income Statement

0.000.00%

Last trade - 00:00

TechnologyHighly SpeculativeMid CapMomentum Trap

Annual income statement for GemVax & KAEL Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	65,663	60,371	75,804	72,209	62,692
Cost of Revenue
Gross Profit	25,548	18,881	21,861	26,048	19,715
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	72,293	62,850	75,483	85,778	101,373
Operating Profit	-6,630	-2,479	322	-13,569	-38,682
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,635	12,058	-19,604	-27,348	-87,803
Provision for Income Taxes
Net Income After Taxes	1,635	12,058	-19,604	-27,177	-87,219
Net Income Before Extraordinary Items
Net Income	1,635	12,058	-19,604	-27,177	-87,219
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,635	12,058	-19,604	-27,177	-87,219
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	254	274	-603	-592	-2,199
Dividends per Share